Dopaminergic signals in the Nucleus Accumbens, VTA and vmPFC underpin extinction learning from omitted threats

Authors: Roland W. Esser¹, Christoph Korn¹, Florian Ganzer¹² & Jan Haaker¹

Affiliations:
¹Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
²German Center for Addiction Research in Childhood and Adolescence, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Running head: Dopaminergic signals underpin threat extinction learning

Corresponding author: Jan Haaker
¹Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Email: j.haaker@uke.de

Summary COI statement: No conflict of interest for any of the authors. The funder had no role in the design of the study, the collection and analysis of data, or the preparation of the manuscript.

Funding/Support: This study was supported by the Collaborative Research Center TRR58 “Fear, Anxiety, Anxiety Disorders”, Project B10 (INST 211/755), funded by the German Research Foundation (DFG) Project number 44541416
Abstract

Learning to be safe is central to adjust behaviour when threats are no longer present. Detecting the absence of an expected threat is key for threat extinction learning and behavioural treatment of anxiety related disorders. One possible mechanism underlying extinction learning is a dopaminergic mismatch signal that encodes absent but expected threats.

We show that a dopamine-related pathway underlies extinction learning in humans. Dopaminergic enhancement (L-DOPA/Placebo) reduced retention of psychophysiological threat responses, which was mediated by activity in the ventromedial prefrontal cortex during extinction learning. L-DOPA administration enhanced signals at the timepoint of the omitted, but expected threat within the nucleus accumbens, which were functionally coupled with the ventral tegmental area and amygdala. Computational modelling of threat expectancies further revealed prediction-error encoding in nucleus accumbens that was modulated by dopaminergic enhancement. Our results provide a mechanism to augment extinction learning by enhancement of dopaminergic neurotransmission that underlies encoding of absent threats.
Introduction

In order to thrive in dangerous environments, it is important to know when threats are disappearing and situations become safe. As such, safety learning is central for adaptive behaviour and deficits characterize symptoms in a wide range of anxiety related disorders [1–4]. Yet, the pharmacological mechanism to augment safety learning by encoding the absence of potential threats or aversive outcomes in humans are not completely understood.

Safety learning is often investigated by laboratory protocols of extinction training. Here, a learned predictor (conditioned stimulus, CS) for an aversive outcome (unconditioned stimulus, US) is turning into a safety signal when the expected aversive outcome is omitted. This omission of the expected US after CS presentation is thought to drive extinction or safety learning. However, it is only incompletely understood in humans which neural system detects the omission of the expected aversive outcome and, hence, initiates a shift from threat to safety. Studies in drosophila [5] and rodents [6–12, 12] revealed that the omission of an expected aversive outcomes depends on signals in the dopaminergic system. In rodents, this involved dopaminergic neurons in the ventral tegmental area (VTA), the nucleus accumbens and the medial prefrontal cortex, as well as projections between the VTA and nucleus accumbens [6, 9, 13, 14]. Importantly, these neural regions were also found to underpin the processing of rewarding outcomes. When signalling rewards, this system does not simply detect a rewarding outcome, but codes a difference between the expected reward and the actual outcome in form of an expectancy violation or prediction error [15]. In other words, reward-related response in the VTA, nucleus accumbens and vmPFC reflect outcomes that are better than expected.

Similarly, the omission of an expected aversive US, which could be framed as “better than expected” and it might well be that this dopaminergic signal at the time-point of US omission encodes an expectancy violation that signals the difference between the expected aversive US and the omitted aversive outcome (for review see[16–18]).
Even though this idea is not formally tested, it is supported by a functional neuroimaging study in humans. This study provided initial tentative evidence that computational modelling of an prediction error for the omitted aversive outcome during extinction training involves activity in the nucleus accumbens and that this activity was modulated by a genetic variance of the dopamine transporter gene [19]. Additionally, there is cross-species evidence for enhanced extinction memory consolidation by augmented dopaminergic transmission after extinction training (by administration of L-DOPA [20–22]). These latter studies suggest that dopaminergic enhancement of extinction memory retrieval is mediated by augmenting activity in the ventral part of the medial prefrontal cortex (vmPFC), a structure that is central for extinction learning and memory retrieval [23–26]. It is, however, not clear if enhancing of dopaminergic neurotransmission would strengthen extinction learning by modulating vmPFC activity.

In this study, we tested if extinction learning is associated with activity changes in the vmPFC and if such activity is modulated by administration of the dopaminergic precursor L-DOPA. We further tested if the unexpected omission of the US during extinction learning is coded in midbrain pathways that connect the VTA and the nucleus accumbens and if activity within this pathway is modulated by L-DOPA. Based on previous studies [20, 22] we hypothesized that L-DOPA treatment would decrease threat responses at retention tests.
Figure 1 | Behavioural and psychophysiological outcome measures

a) US expectancy, b) SCR and c) Fear ratings reflect successful acquisition of CS-US contingencies during acquisition and decreasing responses during extinction training. Retention of CS-US memory was evident during retention test on day 3, as well as initial enhancement of responses after reinstatement within three trials after presentation of the reinstatement USs. We found decreased differential (CS+ - CS-) fear ratings in the retention-test during day 2 in the L-DOPA group, when compared to placebo controls. Hence, the L-DOPA group rated lower fear when the CSs were presented within a new context. Additionally, differential SCRs (CS+ - CS-) in 3 trials after reinstatement were lower in the L-DOPA, when compared to the Placebo group (see figure 2).

Behavioural and physiological outcome measures.

Acquisition of CS-US contingencies on day 1

Participants in both groups learned CS-US contingencies during acquisition training, which was indicated by a CS-type main effect that consisted of enhanced responses to the CS+ as compared to the CS- in all dependent measurements, namely binary (yes/no), trial-wise US expectancy ratings (CS-type main effect in rmANOVAs: US expectancy $F(1,44)=203.9, p<0.001$, $\eta_p^2 =0.823$, mean difference: 0.578 +/- 0.660/0.496 [95%CI], see
Unexpectedly, we found an interaction effect in US expectancy between CS-type, trial and group-status (i.e., subjects that were allocated to receive Placebo or L-DOPA on the next day: CS-type*trial*group $F(2,88)=3.3$, $p=0.044$, $\eta_p^2=0.07$). However, follow-up group comparisons of block-wise US expectancy did not support any differences in CS+ or CS- responses (two-tailed independent post-hoc t-tests: $p>0.1$, see Table. S3) or CS+/CS- discrimination between groups ($p>0.05$, CS discrimination was descriptively lower in the prospective Placebo vs. L-DOPA group, see Table. S3). There was no support for differences between groups in fear ratings or SCRs (group main effect or interaction $p>0.1$, see Table S2).

**Extinction learning on day 2**

On day 2, participants discriminated between CS+ and CS-, as indicated by a main effect of CS-type across all outcome measures (CS-type main effect in rmANOVAs: US expectancy: $F(1,41)=22.3$, $p<0.001$, $\eta_p^2=0.353$, mean difference: $0.183 +/- 0.269/0.106$ [95%CI], SCR: $F(1,38)=23.9$, $p<0.001$, $\eta_p^2=0.386$, mean difference: $0.065 +/- 0.092/0.039$ [95%CI], and fear ratings: $F(1,41)=61.83$, $p<0.001$, $\eta_p^2=0.601$, mean difference: $0.345 +/- 0.434/0.256$ [95%CI]; see Table S4 for full statistics). Responses in all measures decreased over the time course of extinction training (CS-type by block interaction, all $p<0.05$, see Table S4, see Figure 1). In particular, trial-wise US expectancy indicated successful extinction learning of the CS-US association, by evidence for differential CS responses in the first two of three blocks (CS+ > CS-, Block 1: $p<.001$, Block 2 $p=0.48$), but not the last (Block 3: $p=0.57$, see Table S4).

Importantly, the analyses of fear rating indicated only a weak support for an interaction between CS-type, block and group ($F(1,42)=3.884$, $p=0.059$, $\eta_p^2=0.095$). While we found in
accordance with our hypothesis lower differential ratings of fear (CS+ - CS-) at the retention-test on day 2 in the L-DOPA group, when compared to placebo controls, there was again only weak statistical support for this difference (one-sided, post-hoc independent t-test: L-DOPA<Placebo, t(41)=1.911, p(uncorr)=0.032, p(FEW-corr)=0.064, cohen’s d: -0.583, L-DOPA mean: 0.430 +/- 0.523 [SD], Placebo mean: 0.682 +/- 0.322 [SD], see table S5). Exploratory analyses suggested that this effect was driven by lower ratings to the CS+ in the L-DOPA group (one-sided, post-hoc independent t-test: L-DOPA<Placebo, t(42)=1.769, p(uncorr)=0.042, cohen’s d: -0.540, L-DOPA mean: 0.698 +/- 0.338 [SD], Placebo mean: 0.839 +/- 0.159 [SD]), since there was no evidence for difference between groups in CS- ratings (p-values > 0.2, see table S5). Additionally, when we explored the fear ratings to the extinction context, we found marginal support for lower ratings in the L-DOPA group as in subjects that received placebo (one-sided, post-hoc independent t-test: L-DOPA<Placebo, t(42)=1.635, p(uncorr)=0.055, cohen’s d: -0.499, L-DOPA mean: 0.046 +/- 0.109 [SD], Placebo mean: 0.130 +/- 0.210 [SD], see table S5). This might indicate that L-DOPA reduces affective responses of fear to the CS+ when the threat cue is presented within a new context.

We want to highlight that the range-correction of fear ratings (with the individual day-wise maximum) improved this group difference. Still, we found lower differential (non range-corrected) fear ratings during retrieval on day 2 in the L-DOPA group were observed, albeit lower support for statistical difference (one-sided, post-hoc independent t-test: L-DOPA<Placebo, t(41)=1.463, p(uncorr)=0.076, L-DOPA mean: 25.048 +/- 22.723 [SD], Placebo mean: 36.636 +/- 28.681 [SD]). Hence, there is weak support for reduced fear appraisal of the CS+ when this cue is presented in a new context in the L-DOPA group, as compared to the fear ratings in the Placebo group.

We found no statistical evidence that would support a difference between groups in US expectancy ratings or SCR (see Table S4).
Next, we examined how decreasing US expectancy, which indicates extinction learning is driven by expectancy violation from the omission of the US, by fitting US expectancy ratings with a Rescorla-Wager-Pearce-Hall-Hybrid model [27, 28]. The fitted prediction error (as a measure of expectancy violation), associability (as a measure of prediction error-guided surprise) and learning rate did not differ between groups (two-sided independent sample t-test for mean prediction error: $t(40)=0.097$, $p=0.923$, mean associability: $t(40)=0.015$, $p=0.988$, and mean learning rate: $t(40)=0.179$, $p=0.859$, see Table S6).

![Differential SCR (CS+ > CS-) after reinstatement](image)

**Figure 2** | L-DOPA administration during extinction learning decreases SCRs after reinstatement. Differential SCRs (CS+ > CS-) were decreased when compared to the Placebo group within 3 trials after the reinstatement procedure. See figure S1 for CS-specific responses. Asterisk indicate a p-value<0.05 for the CS-type by group interaction and a one-sided t-test.

*Maintenance retrieval on day 3*
At the retrieval test on day 3, participants discriminated between CSs in all outcome measures (CS-type main effect in rmANOVAs: US expectancy: $F(1,41)=23.21$, $p<0.001$, $\eta^2_p=0.193$, mean difference: $0.253 +/- 0.148$ [95%CI]; SCR: $F(1,40)=24.07$, $p<0.001$, $\eta^2_p=0.122$, mean difference: $0.076 +/- 0.045$ [95%CI], and fear ratings: $F(1,41)=54.79$, $p<0.001$, $\eta^2_p=0.578$, mean difference: $0.512 +/- 0.372$ [95%CI]; see Table S7). US expectancy ratings further indicated a general reinstatement of CS+ and CS- responses, when comparing the last three trials before and after the reinstatement USs (see Table S9), but not within a block-wise reinstatement analyses (see table S8).

Importantly, the SCR analyses of the three trials before and after reinstatement revealed a difference between groups in differential CS responses (CS-type by group interaction $F(1,40)=5.443$, $p=0.025$, $\eta^2_p=0.120$, see Table S7 and S8), indicating lower CS discrimination in the L-DOPA group when compared to the Placebo controls after the reinstatement procedure (one-sided, L-DOPA<Placebo post-hoc t-test: $t(40)=2.405$, $p(FWE-corrected)=0.020$, Cohen’s $d=-0.741$, L-DOPA mean: $0.006 +/- 1.31$ [SD], Placebo mean: $0.086 +/- 0.116$ [SD], see Figure 2, S1 and Table S8). While our a priory hypothesis was an effect of L-DOPA on the psychophysiological measurements at retrieval-test on day 3, our analyses suggest that L-DOPA administration during extinction training reduced threat responses after reinstatement.
a) VmPFC responses reflect CS+ trials during extinction training when subjects no longer expected an US that are contrasted with trials in which an US was expected (i.e., extinction learning). **One-sided comparison** L-DOPA > Placebo, MNI xyz: 10, 35, -7; Z = 4.76; Pr{sub}FWE-SVC = .002; displayed at threshold p{sub}unc<.005; colour bar represents t-values. Estimates for activation in the vmPFC were enhanced after administration of L-DOPA as compared to placebo (a.u. = arbitrary units; error-bar indicate the standard error of the mean). (b) Higher individual vmPFC responses across groups that reflect decreasing US expectancy for the CS+ (i.e., extinction learning) are associated with lower conditioned responses (SCR CS+ > CS-) during retrieval test 24 hours later. (c) The effect of L-DOPA treatment on conditioned responses (SCR CS+ > CS-) during retrieval test was fully mediated via the activity of the vmPFC in extinction learning. Drug treatment (L-DOPA vs. Placebo) had an effect on vmPFC activity (β=-2.2957, standard error=0.4227, t(38)=-5.431, p=0.000003), and vmPFC activity had a negative effect on conditioned responses during retrieval test (β=-0.01898, standard error=0.008888 , t(38)= -2.135, p=0.0392). We found no evidence for an effect of drug treatment (L-DOPA vs. Placebo) on conditioned responses during retrieval test (β=0.02644 , standard error=0.03238 , t(38)= 0.816, p=0.419), but when including vmPFC activity into that model, this mediator was significant (β=- 0.02478, standard error=0.01192, t(38)= -2.079, p=0.0446; effect of group p=0.4). There was further evidence for a full mediation of drug treatment (L-DOPA vs. Placebo) on conditioned responses by an indirect effect of vmPFC activity within a mediation model using quasi-bayesian procedures (β=0.0563, 95% confidence intervals = 0.007-0.12, p=0.038, N=40 ,1000 samples, N=40; bootstrapping yielded comparable results (β=0.056, 95% confidence intervals = 0.007-0.14, p=0.044).
Administration of L-DOPA enhances vmPFC responses reflecting decreasing US expectancy during extinction learning

First, our analyses of neural responses focused on the effect of L-DOPA on extinction learning, were we expected an involvement of the vmPFC that is modulated by L-DOPA. To this end we examined brain regions that increased their activity to a decline of US expectation. In order to examine extinction learning by decreasing US expectancy, we contrasted responses during extinction training to CS+ trials when participants expected no US against CS+ trials in which participants expected an US (i.e., expectation of no US > expectation of a US). We found that decreasing US expectancy was accompanied by more pronounced signalling in the right vmPFC in the L-DOPA group as compared to the placebo group (see Figure 3 a). Thus, administration of L-DOPA augmented vmPFC activity during extinction learning, i.e., when participants decreased their US-expectancy.

Next, we tested if this difference in the right vmPFC activity is related to individual differences in extinction memory retrieval. A previous study indicated that vmPFC activation during extinction learning was associated with retention of extinction memory (measured as differential SCR) 24 hours later [20]. Indeed, we found that higher vmPFC activation is associated with reduced differential SCR, i.e., better individual extinction memory retention, 24 hours later (Pearson correlation: t(40) = -2.18, p-value = 0.035, r=-0.326, see Figure 3 b). Hence, vmPFC responses during extinction learning were elevated after L-DOPA administration and such enhanced vmPFC activity is associated with stronger extinction memory retrieval 24 hours later. Importantly, there was no difference between groups detectable in SCRs during retrieval test, which might have biased this correlation [29]. However, it might be possible that L-DOPA treatment has an indirect effect on SCR during retrieval test, which is mediated by vmPFC activity during extinction learning. Indeed, we found support for a treatment effect of L-DOPA on SCRs during retrieval test, which was indirectly mediated by vmPFC activity during extinction learning (average causal mediation effect:
\[ \beta = 0.0563, \text{ 95\% confidence intervals} = 0.007-0.12, \ p=0.038, \text{ quasi-Bayesian estimation of confidence intervals with 1000 iterations, N=40, see figure 3 for detailed statistics).} \]

As such, L-DOPA strengthens vmPFC activation that accompanies decreasing expectation of the US (i.e., extinction learning), which results in better extinction memory retrieval. Our results thereby provide a direct link between L-DOPA augmented vmPFC signalling and the individual time-course of decreasing expectancy of the aversive outcome, which drives extinction learning and memory retrieval.

**Figure 4 | Omission of expected aversive outcomes in the NAcc is modulated by dopamine**

a) At the time-point of US omission the Placebo group exhibited expectancy violation coding (fitted prediction error term) in the right NAcc, which was not observed in participants that received L-DOPA (one-sided comparison Placebo > L-DOPA; MNI xyz: 9, 18, -4; Z = 3.02; \( P_{FWE-SVC} = .043 \)). (b) Administration of L-DOPA abolished negative categorial responses (i.e., independent of expectancy) to omitted USs in the left NAcc that were found in Placebo controls (one-sided comparison L-DOPA > placebo; MNI xyz: -11, 14, -10; Z = 3.22; \( P_{FWE-SVC} = .029 \)). Neural correlates are displayed at threshold \( p_{unc}<.005 \) with bar plot showing parameter estimates (a.u.).
Omission of an expected aversive outcome is coded in the nucleus accumbens and modulated by L-DOPA

In the next step, we examined if decreasing US expectancy during extinction learning is driven by the omission of the US in form of an expectancy violation (i.e., prediction error) and if this process is modulated by dopamine. To this end, we used the modelled US expectancy ratings from the Rescorla-Wagner-Pearce-Hall hybrid model that has previously been used to describe computational processes in associative threat learning [27, 28, 30]. In order to test for signals that reflect expectancy violation, we examined the prediction error term as parametric regressor of responses at the time-point of US omission. We found that activation in the right nucleus accumbens in the Placebo group reflected the time-course of the modelled prediction error term, but not in the L-DOPA group (see figure 4 a). This suggests that the nucleus accumbens in the Placebo group was responsive towards US omissions, only if an aversive outcome was still expected, which reflects the violation of the expected, yet omitted, value. This was supported by an exploratory follow-up analysis, revealing a cluster in the right nucleus accumbens that reflected the expected value at the time-point of US omission (MNI xyz: 9, 18, -4; Z = 3.04; PrFWE-SVC = .040). Of course, PE and value are closely related, since the outcome during extinction training was the same for all trials. Next, we tested, if the L-DOPA group might show responses within the nucleus accumbens that are independent of the prediction error by testing for categorical responses at the time-point of US omission. We found that categorical responses at the time-point of US were higher in the L-DOPA group, compared to Placebo group (see Figure 4 b). In fact, responses in the Placebo group were negative, which would be in line with our finding of expectancy violation coding in the nucleus accumbens: Expectancy violation would be characterized by positive responses in early trials of extinction training (when US expectancy is high) and decreases rapidly with decreasing US expectancy, which could lead to negative responses when averaging a whole time-course. Enhancing dopaminergic transmission (i.e., in the L-DOPA group), in contrast, seems to sustain responses.
to the omitted outcomes in the nucleus accumbens, irrespectively of expectancy of the US or value caching. Hence, our results imply a dopaminergic modulation of expectancy violation in the nucleus accumbens when expected aversive outcomes are omitted during extinction training.

In addition to neural signaling that aligned with the prediction error term, we further investigated potential differences between groups in neural signals that follow the associability term, which provides a measure of prediction error-guided attention shift. We found that administration of L-DOPA enhanced associability related neural signals in the amygdala at the time-point of US omission, when compared to Placebo (see Figure S2). Our results suggest that dopaminergic enhancement might enhance shifting of attention or surprise that is initiated by unexpected omission of the US during extinction training.
Figure 5 | Dopaminergic modulation of functional connectivity between the nucleus accumbens and the VTA at the time-point of US omission

a) Administration of the dopaminergic precursor L-DOPA enhanced connectivity between the bilateral nucleus accumbens (seed, see left) and the left amygdala (one-sided comparison L-DOPA > placebo, MNI xyz: 24 -11 -10; Z=3.73; p(FWE)=0.024), when compared to the Placebo group (contrast L-DOPA > Placebo). b) Dopaminergic enhancement was furthermore associated with strengthened connectivity of the substantia nigra/ventral tegmental area complex and nucleus accumbens (one-sided comparison, L-DOPA=1, Placebo=0; MNI xyz: -8, -16,-15; Z=3.43; p(FWE)=0.039). This contrast is specific to the enhancement of connectivity by L-DOPA, while making no assumptions about the Placebo group. The connectivity was condition-specific to the time-point of US omission (psycho-physiological interaction, PPI in SPM). T-maps are displayed at threshold $p_{unc} < .005$; colour bar represents t-values.

L-DOPA modulates functional connectivity between responses in the nucleus accumbens and the VTA when the US is omitted

Results in animals suggested that processes at the time-point of US omission involve not only the nucleus accumbens, but dopaminergic neurons in the VTA [11] and projections from the VTA to the nucleus accumbens [9], as well as projections from the basolateral complex of the amygdala to the nucleus accumbens [7].
To test if the reported results in the nucleus accumbens at the time-point of the omitted US are functionally connected with other regions in the brain, we employed a condition-specific connectivity analysis with an anatomical nucleus accumbens (bilateral) mask as a seed region. In line with animal data, we found stronger connectivity between the nucleus accumbens and the amygdala in the L-DOPA group when compared to the Placebo group (contrast: L-DOPA > Placebo, see figure 5 a). Moreover, contrasting responses at the time-point of US omission that were specifically improved by dopaminergic enhancement in the L-DOPA group, without making any assumption about the Placebo group (contrast: L-DOPA ≥ Placebo), revealed strengthened connectivity between the nucleus accumbens and the substantia nigra/VTA (SN/VTA) complex, see Figure 5 b). Hence, the activity in the nucleus accumbens during the omitted US is functionally coupled with responses in the amygdala and the SN/VTA and this connectivity is enhanced by administration of L-DOPA.

**Discussion**

Our results provide evidence that dopaminergic processes are involved in threat extinction learning. Dopaminergic enhancement during extinction learning augmented extinction memory at a later test, which was mediated by extinction learning specific vmPFC responses (i.e., reflecting decreasing US expectancy). Decreased US expectancy in extinction learning was further driven by dopaminergic activity within the nucleus accumbens that signalled the omission of expected aversive outcomes. This activity in the nucleus accumbens, when the US was omitted, was functionally coupled with the midbrain SN/VTA complex, as well as the amygdala. Additionally, we found weak statistical support for decreased fear ratings in the retrieval test before extinction training (the CS+ was presented within a new context) in the L-DOPA group when
compared to Placebo, as well as reduced SCRs after the reinstatement one day after extinction learning.

The main finding is that L-DOPA reduced retrieval of conditioned threat responses (SCR) by a mediation through enhanced vmPFC activity. In detail, we found that enhancement of dopaminergic transmission by the administration of L-DOPA (as compared to Placebo) during extinction learning enhanced individual neural signalling in the vmPFC that reflects the reduction of US expectation (i.e., extinction learning). These enhanced vmPFC responses were found to mediate the effect of L-DOPA on extinction memory retention, measured as reduced differential SCRs 24 hours later. Besides the implication of the vmPFC in safety signal processing [31] and threat extinction in humans [23, 24, 26, 32, 33], our results align specifically with a previous finding of vmPFC activity pattern during extinction memory consolidation that mediates the effect of L-DOPA on extinction memory retention [20]. Our results extend this finding on memory consolidation by providing a link between dopaminergic effects on vmPFC activity that is specific for individual extinction learning (i.e., decreasing US expectancy) and augmentation of extinction memory. L-DOPA might have the potential to improve (otherwise low, see parameter estimates in the Placebo group, figure 3 B) vmPFC activity during extinction learning. Hence, rather than enhancing extinction learning per se, L-DOPA administration seems to augment vmPFC responses that accompany decreased US expectancy. This suggests a benefit of L-DOPA for extinction learning processes. Our findings would fit to previous results that link the benefit of neuropharmacological intervention in extinction learning to decreasing threat expectancies [34–36, 36]. Thereby, L-DOPA might have the potential for a psychopharmacological treatment that augments threat extinction learning instead of
dampening overall threat responses, like classic anxiolytics. Additionally, we found that L-DOPA administration during extinction training reduced differential SCRs after reinstatement, which aligns with a finding of decreased SCRs after reinstatement by L-DOPA administration that followed extinction training in women diagnosed with post-traumatic stress disorder [37].

A second set of our results implicate that decrement of US expectancy in extinction training involves a dopaminergic coding of expectancy violation in form of a prediction error at the time-point of US omission. Our study was intentionally not designed to disentangle details of expectancy violation coding of omitted USs, but rather to provide a scenario of safety learning. Nevertheless, we provide evidence for a role of the nucleus accumbens in processing of US omissions, which is in line with a function of the nucleus accumbens in rodents [6, 13, 38] in particular during extinction learning [7, 8, 14, 39]. Our results furthermore align with a previous neuroimaging study reporting an association between prediction error signals in the nucleus accumbens during extinction training and a genetic variant of the dopamine transporter [19]. Our results point moreover to a dopaminergic modulation of surprise in the amygdala that is evoked by US omission, which fits well to previous reports of associability coding in the amygdala during threat learning [27, 30].

We further show that signals in nucleus accumbens at the time-point of US omission were functionally coupled with activation in the amygdala and the SN/VTA, which were enhanced by administration of the dopaminergic precursor L-DOPA. This finding mirrors findings in animals implying neurons in the VTA, as well as projections from the VTA to the nucleus accumbens, in the encoding of the omission of an expected US [9, 11]. Furthermore, our results would align with studies in animals that provided evidence
for amygdala to nucleus accumbens projections that underlie extinction of threat responses [7].

We highlight that our fMRI study in human volunteers is only suited to draw inferences on blood-oxygen-level-dependent signals as a function of L-DOPA administration and hence might imply that activity changes are related to dopaminergic neurotransmission, but invasive studies in animals are needed to confirm that these results are related to dopamine release. We further found that L-DOPA administration did not decrease conditioned responding across all outcome measures that reflect different threat processing, such as US expectancy, psychophysiological arousal (SCR) and affective (fear) ratings. In comparison to the effects of L-DOPA on consolidation of extinction memories [20–22, 34], the reported effect on these outcome measures are rather weak, which might point towards a larger effect of dopaminergic enhancement on consolidation processes. Nevertheless, the effect of L-DOPA to decrease differential SCRs by the mediation of vmPFC activity during extinction learning converges with a previous finding [20] and might suggest that L-DOPA enhances learned decrement of US expectancy (and accompanying vmPFC activity) during extinction training, rather than blunting responses, per se.

In sum, our results thereby provide a neuropharmacological mechanism that augments the neural substrates underling extinction learning in humans [34–36, 36], which could provide a promising novel strategy to augment behavioural treatments of anxiety related disorders [37].
Materials & Methods

Participants

50 healthy male subjects without self-reported psychiatric and neurological diseases and no intake of illegal drugs (urine toxicology) were recruited in this study. Illegal drug-screening test was carried out prior to testing at day 1 (M-10/3-DT; Diagnostik Nord). The final sample in the analyses included 46 participants (L-DOPA N=24, Placebo N=22) after exclusion of four subjects (positive drug urine test N=1, incidental finding of a brain cyst N=1, not following the instructions N=1 and accidental press of the emergency bell N=1).

The sample size of 50 participants (which includes 10 drop-outs) was determined a priori in order to archive a power of 0.95 with an alpha level of 0.05 and assuming an effect size of eta2 =0.08 (previous effect of L-DOPA on extinction memory consolidation, G*Power 3.1.9.6).

The study (including sample size approximation) was approved by local ethics committee in Hamburg (Ärztekammer Hamburg). Full participation of this study was remunerated with 120,-EURO.

Stimulus material

Conditioned stimuli

Contexts surrounding the CSs were employed as virtual reality environments of virtual offices (Source Engine, Valve Corporation, Bellevue, USA, used in Andreatta et al., 2015). Each office image was depicted from two different vantage points (on the wall opposite the door vs. on the wall to the right of the door). Three different contexts were used, context A, context B and a mixture of both in order to induce a contextual generalization [40]. Virtual offices consisted of the same floor plan but differed regarding the furniture. A blue or a yellow color filter illuminating the whole room (duration of 6 sec) served as CSs, indicating either CS+ or CS-. Colors of the CSs and contextual backgrounds were counterbalanced across participants. Presentation of the context served as the inter-trial intervals (ITIs, duration range 7-11 sec, mean 7.8). The visual stimulus material was presented in pseudo-randomized order on a computer screen using Presentation® software (NeuroBehavioral Systems, Albany California, USA).

Unconditioned stimulus

An electrotactile stimulus consisting of a train of 3 square-wave pulses of 2 ms duration each (interval 50 ms) served as the US that the CS+ onset after 5 sec. The US was delivered through a surface electrode with platinum pin (Specialty Developments, Bexley, UK) on the right dorsal hand.
using a DS7A electrical stimulator (Digitimer, Welwyn Garden City, UK). US intensity was individually adjusted prior to acquisition training (day 1) to a level of maximal tolerable pain (mean 8.1 ± 0.5 mA, range 2.5–21.0 mA) and participants were asked to rate the aversiveness of the US between 0 (“I feel nothing”) and 10 (“maximally unpleasant”; rating: mean 7.1 ± 0.1, range 4.0–8.0). Additional US intensity ratings were acquired after fear acquisition training (between 0 and 100 day 1: mean 68.65 ± 3.0, range 20–100) and at the end of return of fear testing (day 3: mean 49.91 ± 3.9, range 0–100). There were no differences between the Placebo and the L-DOPA group in any of these parameters (all $P > .167$; see supplements Table. S1).

**Experimental Procedure**

Using a three-day paradigm, acquisition training (day 1) and extinction training (day 2, approx. 24 h after acquisition) were conducted in the fMRI scanner, while retrieval test (day 3, approx. 24 h after extinction), including reinstatement, were employed within the psychophysiological laboratory. Acquisition training took place in context A, extinction in context B and retrieval test (including reinstatement procedure) in a 50/50-mixture of context A and B in order to examine contextual generalization [40]. Twenty-four hours after acquisition training participants received double-blind, randomized and placebo-controlled 150mg L-DOPA (including 37.5 mg Benserazide) before the extinction learning session (the CS+ was no longer followed by an aversive outcome). L-DOPA administration thereby affected extinction training, while acquisition training, as well as retention and reinstatement-test were conducted drug-free.

**Acquisition training (day 1)**

A short habituation phase preceded acquisition training (6 trials: 3 CS+, 3 CS-) without any presentation of the US. Subsequent acquisition training consisted of 24 trials for each CS (in context A). The CS+ was followed by a US in 75% of the trials, whereas the CS- was never followed by a US. Participants were not informed about the conditioning contingencies or the learning element beforehand.

**Extinction training (day 2)**

Approximately 24 hours after conditioning, participants returned to the fMRI laboratory. US and SCR electrodes were attached exactly as the day before, without US intensity adjustment. During extinction training, 24 trials (context B) were presented for each CS and no US was administered. Participants were not informed beforehand about any change in CS-US contingencies.
Retrieval test and reinstatement (day 3)

Participants returned to the psychophysiological laboratory and US and SCR electrodes were again attached without further US adjustment. A retrieval test (contextual generalization in a 50/50-mixture of context A and B) consisted of 8 unreinforced trials of each CS and was followed by 4 unsignaled reinstatement-USs (interval duration range 10-15 sec). Here, the same individual electrical stimulation intensity was used as during acquisition training. 6-10 sec after the last reinstatement-US, a second retrieval test (reinstatement-test) was employed, including 16 trials (with no US) of each CS. The order of CS+ and CS- after the reinstatement US was counterbalanced across subjects. At the end of the experiment, CS-US contingency awareness was assessed using a semi-structured interview [41] and based on these results 37 participants were classified as aware and 5 were classified as unaware (no differences between groups, χ²-Test, p = .634).

Study medication

Study medication included an oral administration of 150mg L-DOPA (including 37.5 mg Benserazide) in a double-blind and placebo-controlled protocol 60min before extinction learning. Participants were allocate into the placebo or L-DOPA group before day 1 in a restricted randomization procedure that allocated 5 subjects to the L-DOPA and 5 subjects to the placebo group for each group of 10 participants. The dose of 150mg has been found effective in previous studies to enhance the consolidation of extinction memories in humans [20–22].

Outcome measures & analyses

US expectancy

On each CS trial presentation, participants had to rate their US expectancy as a binary choice (key press for yes/no) without any scale presented to avoid any distraction. Participants were excluded from the analyses (day-wise) if less than one third of all data points were missing [excluded participants: N(day 1)=0, N(day 2)=3, N(day 3)=3].

Fear ratings

At the beginning as well as at the end of each experimental day, participants were asked to rate the fear/stress/tension level that was elicited by each CS. On day 1 the first rating was conducted after habituation phase and before acquisition training. Ratings were performed on a computerized
Visual Analogue Scale [VAS, 0 (none) – 100 (maximal)] using keys with the right hand. Rating values had to be confirmed by a key press (otherwise missing data, N(day 1)=0, N(day 2)=3, N(day 3)=4). All rating values were range-corrected (divided by the maximal rating value on that day).

Skin conductance

Skin conductance responses (SCRs) was measured via self-adhesive Ag/AgCl electrodes placed on the palmar side of the left hand on the distal and proximal hypothenar. Data were recorded with a BIOPAC MP-100 amplifier (BIOPAC Systems Inc, Goleta, California, USA) using AcqKnowledge 4 software. For data analysis, SCR signal was down-sampled to 10 Hz and responses were manually scored between 0.9 to 4.0 s after CS onset using a custom-made computer program. Non-reactions were scored as zero and trials with obvious electrode artefacts were scored as missing data. Afterwards, amplitudes were logarithmized and range-corrected (SCR/SCRmax CS [day]) separately for the three consecutive experimental days in order to account for inter-individual variability. SCR data from a limited number of participants had insufficient data quality (as judged by two researchers; due to signal-disturbances by the fMRI acquisition) and were thus excluded (day-wise) before the analyses [N(day 1)=1, N(day 2)=6, N(day 3)=4]. Trial-wise SCRs were then averaged over a block of 8 trials, resulting in 3 blocks on each day.

Analytic strategy

Outcome measures were analyzed (using JASP 0.11.1) employing repeated-measures ANOVAs. For acquisition and extinction training, these ANOVAs included CS-type (2) and the effect of time (fear ratings: 2 ratings, SCR and US expectancy: 3 blocks, each average across 8 trials). Pharmacological group was entered as a between subject factor. For day 3, we analyzed the first block separately as the retrieval test and the reinstatement analyses included two comparisons of trials before and after the reinstatement USs [42]. First, we compared responses averaged across the whole block (8 trials) before and after reinstatement. Since reinstatement effect are transient and only detectable over a few trials, we added a second, more detailed analysis, which compared responses averaged across the 3 trials before and after reinstatement, based on previous findings indicating that transient reinstatement effects can be found up to 3 trials after the US presentation [43]. In all analyses, an α-level of p<0.05 was adopted and sphericity correction (Greenhouse-Geisser) was applied.

Follow-up post-hoc test on measurement on day 2 and 3 were performed as one-sided independent t-test to examine the hypothesis of L-DOPA responses < Placebo responses. During data acquisition, preprocessing and initial analyses, the experimenter were masked to the drug conditions.
**Hybrid model**

To examine how decreasing US expectancy is driven by expectancy violation from the omission of the US, we fitted trial-wise US expectancy ratings with a Rescorla-Wager-Pearce-Hall-Hybrid model, which is the same model employed in previous neurocomputational studies of aversive learning in humans [27, 28]).

In order to examine associative threat learning processes, which can be described by classical formal learning theory such as the Rescorla-Wagner (R-W) (Rescorla and Wagner, 1972a) and Pearce-Hall (P-H) model (Pearce and Bouton, 2001), we analyzed extinction learning underlying mechanisms based on trial-by-trial US expectancy ratings. Therefore, a Rescorla-Wager-Pearce-Hall-Hybrid model (HM) (Pelley, 2004) was used, which algebraically describes error-driven learning based on prediction errors (PE, i.e., mismatches) between the predicted (aversive) outcomes (denoted as expected “values,” $v$) and the received outcomes (RO), which in this case corresponded to the omissions of the US. Extending the RW-model, the HM explicitly accounts for dynamically changing learning rates $\alpha$ (i.e., surprising absence of the US) that is updated depending on the associability $\eta$ (i.e., the reliability of prior predictions). That means the associability $\eta$ increases in proportion to the absolute prediction error (PE) on the last interaction with a stimulus, allowing the agent to adapt to changing environments, which leads to larger prediction errors (PE), and thereby higher associability $\eta$. The hybrid model (HM) is formalized by the following equation:

$$v_{t+1} = v_t + \alpha \cdot \eta_t \cdot PE$$

The predicted “values” ($v$) on the next trial $t+1$ are based on the “value” at the current trial $t$ and on prediction errors (PE) scaled by the learning rate $\alpha$ and the current associability $\eta_t$.

Prediction errors (PE) are calculated as the difference between the current predicted values ($v_t$) and the received outcomes (RO).

$$PE = RO - v_t$$

The current associability $\eta_t$ is updated according to the absolute prediction error (PE) and the associability of the preceding trial $\eta_{t-1}$ with the free scaling parameter $\omega$.

$$\eta_t = \omega \cdot abs(PE) + (1 - \omega) \cdot \eta_{t-1}$$

The model employs a softmax function with a free “inverse temperature” parameter $\beta$ to generate trial-by-trial probabilities ($p$) for the binary US expectancy ratings.
The model thus contains three free parameters: (i) the learning rate $\alpha$, (ii) the scaling parameter $\omega$ for the associability $\eta$, and (iii) the inverse temperature parameter $\beta$. These three free parameters were initialized in the fitting procedure as 0.5, 0.5, and 4, respectively. The starting point for the initial “value” $v_0$ was set to 0.75, i.e., the probability for a US following a CS+ in the acquisition phase. The starting point for the initial associability $\eta_0$ was set to 1, which assumes that the associability is initially fully dependent on the prediction error (PE). We fitted model parameters using maximum likelihood estimation (MLE). Specifically, we used the non-linear Nelder-Mead simplex search algorithm (implemented in the MATLAB function fminsearch) to minimize negative log-likelihood summed over all trials for each participant.

**fMRI acquisition and analysis**

MRI data were obtained on a 3T Magnetom-PRISMA System (Siemens, Erlangen, Germany) using a 64-channel head coil. fMRI measurements were performed using single-shot echo-planar imaging with parallel imaging (GRAPPA, in-plane acceleration factor 2) [44] and simultaneous multi-slice acquisitions (“multiband”, slice acceleration factor 2 [45, 45, 46] as described in [47]. The corresponding image reconstruction algorithm was provided by the University of Minnesota Center for Magnetic Resonance Research. Echo planar multiband images were acquired with 42 continuous axial slices (1.5 mm thickness, 0.5 mm gap) in a $T_2^*$-sensitive sequence (TR = 1493 ms, TE = 30 ms, flip angle = 60°, field of view = $225 \times 225$ mm$^2$). Selection of slice arrangement was individually adjusted in order to cover the following areas: dorsal anterior cingulate cortex, ventral medial prefrontal cortex, nucleus accumbens, amygdala, and midbrain SN/VTA. Moreover, high-resolution T1-weighted structural brain image (MP-RAGE sequence, 1 mm isotropic voxel size, 240 slices) were obtained.

For task-relevant functional data of day 2 (extinction training), preprocessing and statistical analysis was carried out using SPM12 (Statistical Parametric Mapping, [http://www.fil.ion.ucl.ac.uk/spm](http://www.fil.ion.ucl.ac.uk/spm)) running under Matlab2017a (The MathWorks, Inc., Natick, Massachusetts, United States). To account for T1 equilibrium effects, the first five volumes of each time series were discarded. All remaining images were unwarped, realigned to the first image, coregistered to the individual high resolution T1 structural image. Subsequent statistical analyses were performed by using a standard approach for fMRI implemented in the SPM software, involving a general linear convolution model.
(GLM) at the single-subject level and a random-effects analysis on group level. On individual-level, experimental conditions (i.e., ITI, CS+, CS−, omitted US, introductions, ratings, and button presses) were defined as separate regressors modeling the predicted time courses of experimentally induced brain activation changes as a stick function. Furthermore, CS+ regressors included a parametric modulation of individual US expectancy ratings in order to examine dopamine-dependent differences in neural representation in decreasing US expectancy during extinction learning. Additionally, parametrical modulation of the omitted US was applied to examine neural responses that are related to changes in expectancy-violation over trials. Therefore, the modelled prediction error-term (as a measure of expectancy violation, averaged across the whole sample) and the orthogonalized associability-term (as a measure of prediction error-guided surprise, averaged across the whole sample) was entered trial-wise.

In a next step, subject- and regressor-specific parameter estimate images of interest were normalized to a sample-customized DARTEL template [48] smoothed with an isotropic full-width at half-maximum Gaussian kernel of 4 mm. These estimates were then included into separate random-effects group analysis using SPM’s “full factorial” model, which permits correction for possible non-sphericity of the error term (here, dependence of conditions). Model factors for the respective analysis were CS+*US expectancy ratings (extinction learning), omitted US*mean prediction error and omitted US*associability (expectancy violation), always including the factor group (Placebo, L-DOPA). Analyses main objective was to reveal dopamine-specific effects (L-DOPA vs Placebo) during extinction learning depending on time-point related changes in US expectation. Significance of effects was tested by using voxel-wise one-tailed t tests. According to our hypotheses, we expected enhanced signaling in the L-DOPA group as compared to the Placebo group in CS+*US expectancy ratings (extinction learning) in the vmPFC (L-DOPA > Placebo). We further expected a modulation of omitted US signals by L-DOPA administration and examined all contrast for the timepoint of US omission (omitted US*mean prediction error, omitted US*associability, categorical omitted US) in both directions (L-DOPA> Placebo and Placebo> L-DOPA).

Regions of interest (ROI) were the defined as 1) dopaminergic innervated key structures, such as the nucleus accumbens and the VTA/SN and 2) key structures in extinction learning, such as the amygdala 54 and the vmPFC. These structures were defined by Havard-Oxford probability maps for the nucleus accumbens and the amygdala. For the SN/VTA and vmPFC is no anatomical mask available, therefore we defined both ROIs as in a previous study that revealed an effect of L-DOPA treatment in both, the SN/VTA and vmPFC ROI [49]. The SN/VTA complex was defined by [50]. The vmPFC ROI was defined as a box of 20 × 16 × 16 mm at x=0 y=42 z=-12 . Correction for multiple comparisons within these ROIs was performed by using family-wise error correction based on the Gaussian Random Fields as implemented in SPM.
Connectivity analysis

Psycho-physiological interaction (PPI, as implemented in SPM12) was used to examine functional connectivity differences of responses in the nucleus accumbens towards the omitted US between groups. Extracted eigenvariates of nucleus accumbens (bilateral ROI mask) were used as the seed region, deconvolved and multiplied with the condition specific onsets of the omitted US. The product (PPI) was entered as a regressor into an individual GLM for each participant, controlling for the time-course of the nucleus accumbens, the onset regressor and movement as nuisance regressors. Parameter estimates of the omitted US-PPI were then contrasted between groups.

Mediation analysis

To test if the effect of L-DOPA vs Placebo on differential SCRs at retrieval test on day 3 was mediated by the activity in the vmPFC that aligned with decreasing US expectancy, we employed a mediation analysis (R Studio, Version 1.2.1335, package “mediation”). This analysis was based on a prior analysis that revealed that effects of L-DOPA on extinction memory retention (differential SCRs during retention test) were mediated by vmPFC activity during consolidation [20].

Acknowledgements
The authors thank Smilla Weisser for support with the recruitment of participants and Katrin Bergholz, Kathrin Wendt and Waldemar Schwarz for help with MR-data acquisition. We further thank Jürgen Finsterbusch for the development of the MRI sequence and the authors are grateful to the University of Minnesota Center for Magnetic Resonance Research for providing the image reconstruction algorithm for the simultaneous multi-slice acquisitions.

Competing interests:
The authors declare no competing interests.

Author contributions:
JH and RWE designed the experiment, RWE and FG acquired the data, RWE, JH and CWK analyzed the data, RWE and JH wrote the manuscript and all authors provided comments on the manuscript.

Data availability:
Source data for the analyses and figures is available at: https://osf.io/6tfu3/?view_only=50493b0ad31f4801953873363f9f9ec2
References:

1. Duits P, Cath DC, Lissek S, Hox JJ, Hamm AO, Engelhard IM, et al. Updated meta-analysis of classical fear conditioning in the anxiety disorders. Depress Anxiety. 2015;32:239–253.
2. Fenster RJ, Lebois TAM, Ressler KJ, Suh J. Brain circuit dysfunction in post-traumatic stress disorder: from mouse to man. Nature Reviews Neuroscience. 2018;19:535–551.
3. Lissek S, Powers AS, McClure EB, Phelps EA, Woldehawariat G, Grillon C, et al. Classical fear conditioning in the anxiety disorders: a meta-analysis. Behav Res Ther. 2005;43:1391–1424.
4. Milad MR, Quirk GJ. Fear Extinction as a Model for Translational Neuroscience: Ten Years of Progress. Annual Review of Psychology. 2012;63:129–151.
5. Felsenberg J, Jacob PF, Barnstedt O, Edmondson-Stait AJ, Pleijzier MW, et al. Integration of Parallel Opposing Memories Underlies Memory Extinction. Cell. 2018;175:709–722.e15.
6. Badrinarayan A, Wescott SA, Vander Weele CM, Saunders BT, Couturier BE, Maren S, et al. Aversive stimuli differentially modulate real-time dopamine transmission dynamics within the nucleus accumbens core and shell. J Neurosci. 2012;32:15779–15790.
7. Correia SS, McGrath AG, Lee A, Graybiel AM, Goosens KA. Amygdala-ventral striatum circuit activation decreases long-term fear. Elife. 2016;5.
8. Holtzman-Assif O, Laurent V, Westbrook RF. Blockade of dopamine activity in the nucleus accumbens impairs learning extinction of conditioned fear. Learning & Memory. 2010;17:71–75.
9. Luo R, Uematsu A, Weitemier A, Aquili L, Koivumaa J, McHugh TJ, et al. A dopaminergic switch for fear to safety transitions. Nature Communications. 2018;9:2483.
10. Mueller D, Bravo-Rivera C, Quirk GJ. Infralimbic D2 receptors are necessary for fear extinction and extinction-related tone responses. Biol Psychiatry. 2010;68:1055–1060.
11. Salinas-Hernández XI, Vogel P, Betz S, Kalisch R, Sigurdsson T, Duvarcí S. Dopamine neurons drive fear extinction learning by signaling the omission of expected aversive outcomes. Elife. 2018;7:e38818.
12. Zhang X, Kim J, Tonegawa S. Amygdala Reward Neurons Form and Store Fear Extinction Memory. Neuron. 2020:S0896627319310918.
13. Oleson EB, Gentry RN, Chioma VC, Cheer JF. Subsecond Dopamine Release in the Nucleus Accumbens Predicts Conditioned Punishment and Its Successful Avoidance. Journal of Neuroscience. 2012;32:14804–14808.
14. Rodríguez-Romaguera J, Do Monte FHM, Quirk GJ. Deep brain stimulation of the ventral striatum enhances extinction of conditioned fear. Proceedings of the National Academy of Sciences. 2012;109:8764–8769.
15. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science. 1997;275:1593–1599.
16. Abraham AD, Neve KA, Lattal KM. Dopamine and extinction: A convergence of theory with fear and reward circuitry. Neurobiology of Learning and Memory. 2014;108:65–77.
17. Kalisch R, Gerlicher AMV, Duvarcí S. A Dopaminergic Basis for Fear Extinction. Trends in Cognitive Sciences. 2019;23:274–277.
18. Nasser HM, McNally GP. Appetitive–aversive interactions in Pavlovian fear conditioning. Behavioral Neuroscience. 2012;126:404–422.
19. Raczkà KA, Mechias ML, Gartmann N, Reif A, Deckert J, Pessiglione M, et al. Empirical support for an involvement of the mesostriatal dopamine system in human fear extinction. Translational Psychiatry. 2011;1:e12.
20. Gerlicher AMV, Tüscher O, Kalisch R. Dopamine-dependent prefrontal reactivations explain long-term benefit of fear extinction. Nat Commun. 2018;9:4294.
21. Haaker J, Lonsdorf TB, Kalisch R. Effects of post-extinction l-DOPA administration on
the spontaneous recovery and reinstatement of fear in a human fMRI study. Eur Neuropsychopharmacol. 2015. 21 July 2015. https://doi.org/10.1016/j.euroneuro.2015.07.016.

22. Haaker J, Gaburro S, Sah A, Gartmann N, Lonsdorf TB, Meier K, et al. Single dose of L-dopa makes extinction memories context-independent and prevents the return of fear. Proc Natl Acad Sci USA. 2013;110:E2428-2436.

23. Kalisch R, Korenfeld E, Stephan KE, Weiskopf N, Seymour B, Dolan RJ. Context-dependent human extinction memory is mediated by a ventromedial prefrontal and hippocampal network. J Neurosci. 2006;26:9503–9511.

24. Milad MR, Wright CI, Orr SP, Pitman RK, Quirk GJ, Rauch SL. Recall of fear extinction in humans activates the ventromedial prefrontal cortex and hippocampus in concert. Biol Psychiatry. 2007;62:446–454.

25. Milad MR, Quirk GJ. Neurons in medial prefrontal cortex signal memory for fear extinction. Nature. 2002;420:70–74.

26. Phelps EA, Delgado MR, Nearing KI, LeDoux JE. Extinction learning in humans: role of the amygdala and vmPFC. Neuron. 2004;43:897–905.

27. Boll S, Gamer M, Gluth S, Finsterbusch J, Büchel C. Separate amygdala subregions signal surprise and predictiveness during associative fear learning in humans. Eur J Neurosci. 2013;37:758–767.

28. Li J, Schiller D, Schoenbaum G, Phelps EA, Daw ND. Differential roles of human striatum and amygdala in associative learning. Nat Neurosci. 2011;14:1250–1252.

29. Makin TR, Orban de Xivry J-J. Ten common statistical mistakes to watch out for when writing or reviewing a manuscript. ELife. 2019;8:e48175.

30. Lindström B, Haaker J, Olsson A. A common neural network differentially mediates direct and social fear learning. Neuroimage. 2018;167:121–129.

31. Harrison BJ, Fullana MA, Via E, Soriano-Mas C, Vervliet B, Martínez-Zalacaín I, et al. Human ventromedial prefrontal cortex and the positive affective processing of safety signals. Neuroimage. 2017;152:12–18.

32. Ball TM, Knapp SE, Paulus MP, Stein MB. Brain activation during fear extinction predicts exposure success: Ball et al. Depress Anxiety. 2017;34:257–266.

33. Merz CJ, Hamacher-Dang TC, Stark R, Wolf OT, Hermann A. Neural Underpinnings of Cortisol Effects on Fear Extinction. Neuropsychopharmacol. 2018;43:384–392.

34. Gerlicher AMV, Tüscher O, Kalisch R. L-DOPA improves extinction memory retrieval after successful fear extinction. Psychopharmacology. 2019;236:3401–3412.

35. Hofmann SG. CYCLOSERINE FOR TREATING ANXIETY DISORDERS: MAKING GOOD EXPOSURES BETTER AND BAD EXPOSURES WORSE. Depress Anxiety. 2014;31:175–177.

36. Smits JAJ, Rosenfield D, Otto MW, Marques L, Davis ML, Meuret AE, et al. D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res. 2013;47:1455–1461.

37. Cisler JM, Privratsky AA, Sartín-Tarm A, Sellnow K, Ross M, Weaver S, et al. L-DOPA and consolidation of fear extinction learning among women with posttraumatic stress disorder. Transl Psychiatry. 2020;10:287.

38. Budygin EA, Park J, Bass CE, Grinevich VP, Bonin KD, Wightman RM. Aversive stimulus differentially triggers subsecond dopamine release in reward regions. Neuroscience. 2012;201:331–337.

39. Whittle N, Schmuckermair C, Gunduz Cinar O, Hauschild M, Ferraguti F, Holmes A, et al. Deep brain stimulation, histone deacetylase inhibitors and glutamatergic drugs rescue resistance to fear extinction in a genetic mouse model. Neuropharmacology. 2013;64:414–423.

40. Andreatta M, Leombruni E, Glotzbach-Schoon E, Pauli P, Mühlberger A. Generalization of Contextual Fear in Humans. Behavior Therapy. 2015;46:583–596.
41. Bechara A, Tranel D, Damasio H, Adolphs R, Rockland C, Damasio AR. Double dissociation of conditioning and declarative knowledge relative to the amygdala and hippocampus in humans. Science. 1995;269:1115–1118.
42. Haaker J, Golkar A, Hermans D, Lonsdorf TB. A review on human reinstatement studies: an overview and methodological challenges. Learn Mem. 2014;21:424–440.
43. Scharfenort R, Lonsdorf TB. Neural correlates of and processes underlying generalized and differential return of fear. Soc Cogn Affect Neurosci. 2016;11:612–620.
44. Griswold MA, Jakob PM, Heidemann RM, Nittka M, Jellus V, Wang J, et al. Generalized autocalibrating partially parallel acquisitions (GRAPPA). Magn Reson Med. 2002;47:1202–1210.
45. Feinberg DA, Moeller S, Smith SM, Auerbach E, Ramanna S, Glasser MF, et al. Multiplexed Echo Planar Imaging for Sub-Second Whole Brain FMRI and Fast Diffusion Imaging. PLoS ONE. 2010;5:e15710.
46. Moeller S, Yacoub E, Olman CA, Auerbach E, Strupp J, Harel N, et al. Multiband multislice GE-EPI at 7 tesla, with 16-fold acceleration using partial parallel imaging with application to high spatial and temporal whole-brain fMRI. Magn Reson Med. 2010;63:1144–1153.
47. Setsompop K, Gagoski BA, Polimeni JR, Witzel T, Wedeen VJ, Wald LL. Blipped-controlled aliasing in parallel imaging for simultaneous multislice echo planar imaging with reduced $g$-factor penalty: Blipped-CAIPI for Simultaneous Multislice EPI. Magn Reson Med. 2012;67:1210–1224.
48. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007;38:95–113.
49. Lonsdorf TB, Haaker J, Kalisch R. Long-term expression of human contextual fear and extinction memories involves amygdala, hippocampus and ventromedial prefrontal cortex: a reinstatement study in two independent samples. Soc Cogn Affect Neurosci. 2014. 11 March 2014. https://doi.org/10.1093/scan/nsu018.
50. Bunzeck N, Düzel E. Absolute Coding of Stimulus Novelty in the Human Substantia Nigra/VTA. Neuron. 2006;51:369–379.
**Supplementary materials**

Dopaminergic signals in the Nucleus Accumbens, VTA and vmPFC underpin extinction learning from the omission of expected threats

Table S1: No differences in US intensity and US valence ratings, maximums of ratings for the CSP or CSM.

| condition     | measure                        | condition     | measure                        | N             | T     | df       | P       |
|---------------|--------------------------------|---------------|--------------------------------|---------------|-------|----------|---------|
| Calibration   | US strength (micro Ampere)     | PLC N=22,     | PLC N=22,                       | 1.409         | 38.737| .167     |         |
|               |                                | L-DOPA N=24   | L-DOPA N=24                     |               |       |          |         |
|               | Rated US valence               | PLC N=21,     | PLC N=21,                       | -.843         | 42.999| .404     |         |
|               |                                | L-DOPA N=24   | L-DOPA N=24                     |               |       |          |         |
| Conditioning  | Rated US intensity             | PLC N=22,     | PLC N=22,                       | -.279         | 43.769| .782     |         |
|               |                                | L-DOPA N=24   | L-DOPA N=24                     |               |       |          |         |
|               | CSs rating max (d1)            | PLC N=22,     | PLC N=22,                       | -1.280        | 41.957| .208     |         |
|               |                                | L-DOPA N=24   | L-DOPA N=24                     |               |       |          |         |
| Extinction    | CSs rating max (d2)            | PLC N=22,     | PLC N=22,                       | -.845         | 40.733| .403     |         |
|               |                                | L-DOPA N=21   | L-DOPA N=21                     |               |       |          |         |
| Return of fear| Rated US intensity             | PLC N=22,     | PLC N=22,                       | 1.162         | 40.999| .252     |         |
|               |                                | L-DOPA N=21   | L-DOPA N=21                     |               |       |          |         |
|               | CSs rating max (d3)            | PLC N=21,     | PLC N=21,                       | .525          | 40.852| .603     |         |
|               |                                | L-DOPA N=24   | L-DOPA N=24                     |               |       |          |         |

Please note that US intensity was not calibrated again on day 2 (extinction) or day 3 (return of fear).
### Table S2: Fear acquisition training

| Effect               | Measure                | N     | F     | Df (GG) | P      | Partial Eta² | Post-hoc (uncorr.) |
|----------------------|------------------------|-------|-------|---------|--------|--------------|--------------------|
| CS-type              | Fear rating            | P=22  | 116.034 | 1.44 | < .001 | .725         | CS+ > CS-, < .001  |
|                      | US-expectancy          | P=22  | 203.904 | 1.44 | < .001 | .823         | CS+ > CS-, < .001  |
|                      | SCR                    | P=21  | 41.734  | 1.43 | < .001 | .493         | CS+ > CS-, < .001  |
| CS-type * group      | Fear rating            | P=22  | .046   | 1.44  | .831   | .001         |                    |
|                      | US-expectancy          | P=22  | 1.390  | 1.44  | .245   | .031         |                    |
|                      | SCR                    | P=21  | .179   | 1.43  | .674   | .004         |                    |
| Time * group         | Fear rating            | P=22  | 2.775  | 1.44  | .103   | .059         |                    |
|                      | US-expectancy          | P=22  | .180   | 1.9   | .846   | .004         |                    |
|                      | SCR                    | P=21  | .331   | 1.43  | .709   | .008         |                    |
| CS-type * time * group| Fear rating           | P=22  | .013   | 1.44  | .911   | < .001       |                    |
|                      | US-expectancy          | P=22  | 3.307  | 1.9   | 83.1   | .044         | .070               |
|                      | SCR                    | P=21  | .161   | 1.43  | .850   | .004         |                    |

All CS by group comparisons p>0.1, see Table S3
Table S3: **Post-hoc comparisons** CS-type * Time * group in US expectancy ratings.  
Independent Samples T-Test (2-sided, Placebo vs. L-DOPA, since there is was hypothesis for day 1)

| MEAN CS+ Block 1  | t    | df  | P (uncorrected) |
|-------------------|------|-----|-----------------|
| -0.099            | -0.099 | 44.000 | 0.922          |
| MEAN CS+ Block 2  | 1.204 | 44.000 | 0.235          |
| MEAN CS+ Block 3  | 1.634 | 44.000 | 0.109          |
| MEAN CS- Block 1  | -0.014 | 44.000 | 0.989          |
| MEAN CS- Block 2  | -1.310 | 44.000 | 0.197          |
| MEAN CS- Block 3  | -1.362 | 44.000 | 0.180          |
| diff_US_exp_mean_B1 | -0.060 | 44.000 | 0.953          |
| diff_US_exp_mean_B2 | 1.596  | 44.000 | 0.118          |
| diff_US_exp_mean_B3 | 1.761  | 44.000 | 0.085          |
Table S4: Extinction effect

| effect          | measure             | N               | F     | df (GG) | P      | Eta²   | Post-hoc (Holm-bonf. corrected) |
|-----------------|---------------------|-----------------|-------|---------|--------|--------|---------------------------------|
| CS-type         | Fear rating         | P=22, LD=21     | 61.830| 1,41    | <.001  | .601   | CS+ > CS-, p< .001              |
|                 | US expectation      | P=22, LD=21     | 22.327| 1,41    | <.001  | .353   | CS+ > CS-, p< .001              |
|                 | SCR                 | P=20, LD=20     | 23.861| 1,38    | <.001  | .386   | CS+ > CS-, p< .001              |
| Time            | Fear rating         | P=22, LD=21     | 91.629| 1,41    | <.001  | .691   | CS+ > CS- Block 1               |
|                 | US expectation      | P=22, LD=21     | 54.929| 1,61    | <.001  | .156   | Block 1> Block 2, p<.001       |
|                 | SCR                 | P=20, LD=20     | 66.633| 1,47    | <.001  | .637   | Block 1> Block 2 > Block 3, ps<.001 |
| CS-type * time  | Fear rating         | P=22, LD=21     | 50.081| 1,41    | <.001  | .550   | CS+ > CS- Block 1               |
|                 | US expectation      | P=22, LD=21     | 25.804| 1,72    | <.001  | .043   | CS+ > CS- Block 1               |
|                 | SCR                 | P=20, LD=20     | 4.202 | 1.68    | .253   | .036   | Block 1> Block 2, p<.001       |
| CS-type * group | Fear rating         | P=22, LD=21     | 2.341 | 1,41    | .134   | .054   | CS+ > CS- Block 1               |
|                 | US expectation      | P=22, LD=21     | .001  | 1,41    | .977   | <.001  | CS+ > CS- Block 1               |
|                 | SCR                 | P=20, LD=20     | .003  | 1,38    | .955   | <.001  | CS+ > CS- Block 1               |
| Time * group    | Fear rating         | P=22, LD=21     | .169  | 1,41    | .683   | .004   | CS+ > CS- Block 1               |
|                 | US expectation      | P=22, LD=21     | 1.392 | 1,41    | .253   | .033   | CS+ > CS- Block 1               |
|                 | SCR                 | P=20, LD=20     | 1.435 | 1,38    | .243   | .036   | CS+ > CS- Block 1               |
| CS-type * time  | Fear rating         | P=22, LD=21     | 3.784 | 1,41    | .059   | .084   | CS+ > CS- Block 1               |
| group           | US expectation      | P=22, LD=21     | .367  | 1,41    | .667   | .009   | CS+ > CS- Block 1               |
|                 | SCR                 | P=20, LD=20     | .178  | 1,38    | .809   | .005   | CS+ > CS- Block 1               |
| group           | Fear rating         | P=22, LD=21     | .0336 | 1,41    | .565   | .008   | CS+ > CS- Block 1               |
|                 | US expectation      | P=22, LD=21     | .001  | 1,41    | .972   | <.001  | CS+ > CS- Block 1               |
|                 | SCR                 | P=20, LD N=20   | 1.038 | 1,38    | .315   | .027   | CS+ > CS- Block 1               |
### Table: S5 Group comparisons of differential (CS+ > CS-) fear ratings on day 2 between L-DOPA and Placebo (one-sided Independent Samples T-Test, L-DOPA > Placebo)

|                          | t    | df     | P (uncorr) | P(Holm-Bonferroni) | Cohen's d |
|--------------------------|------|--------|------------|---------------------|-----------|
| Differential rating CS+ > CS- pre | -1.911 | 41.000 | 0.032      | 0.064               | -0.583    |
| Differential rating CS+ > CS- post  | -0.246 | 41.000 | 0.403      | 0.403               | -0.075    |
| CS+ rating pre           | -1.769 | 41.000 | 0.042      | exploratory         | -0.540    |
| CS+ rating post          | -0.659 | 41.000 | 0.257      | exploratory         | -0.201    |
| CS- rating pre           | 1.231  | 41.000 | 0.887      | exploratory         | 0.375     |
| CS- rating post          | -0.464 | 41.000 | 0.322      | exploratory         | -0.142    |
| ITI (context) rating pre | -1.635 | 41.000 | 0.055      | exploratory         | -0.499    |
| ITI (context) rating post| 0.611  | 41.000 | 0.728      | exploratory         | 0.186     |

*Note.* For all tests, the alternative hypothesis specifies that L-DOPA group is less than Placebo.

### Table: S6 Group comparisons between L-DOPA and Placebo for Pearce-Hall mean model estimates (Independent Samples T-Test)

|                  | t    | df     | p     |
|------------------|------|--------|-------|
| Prediction error | 0.097| 39.993 | 0.923 |
| Associability    | 0.015| 39.998 | 0.988 |
| Learning rate    | 0.179| 39.383 | 0.859 |
| BIC              | -0.411| 34.299 | 0.684 |
| LLE              | -0.411| 34.299 | 0.684 |
| Value            | -0.097| 39.988 | 0.924 |

*Abbreviations:* BIC = Bayesian information criterion, LLE =

*Note.* For all tests, the alternative hypothesis specifies that L-DOPA group is less than Placebo.
Table S7: Retrieval test

| effect            | measure              | N               | Retrieval test | F     | Df (GG) | P       | Post-hoc (Holm-bonf. corrected) |
|-------------------|----------------------|-----------------|----------------|-------|---------|---------|---------------------------------|
| CS-type           | Fear rating          | PLC N=21, L-DOPA N=21 | 54.79          | 1.40  | < .001  | .578    | CS+ > CS-, < .001               |
|                   | US expectancy        | PLC N=22, L-DOPA N=21 | 15.172         | 1.41  | < .001  | .270    | CS+ > CS-, < .001               |
|                   | SCR                  | PLC N=21, L-DOPA N=21 | 24.071         | 1.40  | < .001  | .122    | CS+ > CS-, < .001               |
| CS-type * group   | Fear rating          | PLC N=21, L-DOPA N=21 | 1.229          | 1.40  | .274    | .030    |                                 |
|                   | US expectancy        | PLC N=22, L-DOPA N=21 | .010           | 1.41  | .921    | .001    |                                 |
|                   | SCR                  | PLC N=21, L-DOPA N=21 | .005           | 1.40  | .496    | .002    |                                 |
| group             | Fear rating          | PLC N=21, L-DOPA N=21 | .233           | 1.41  | .632    | .006    |                                 |
|                   | US expectancy        | PLC N=22, L-DOPA N=21 | .892           | 1.41  | .351    | .021    |                                 |
|                   | SCR                  | PLC N=20, L-DOPA N=20 | 0.027          | 1.40  | .870    | .001    |                                 |
Reinstatement analyses

**Table S8: Reinstatement test (block 1 vs block 2)**

| effect              | measure       | Reinstatement (blockwise comparisons) | F    | Df (GG) | P      | Eta² | Post-hoc (Holm-bonf. corrected) |
|---------------------|---------------|----------------------------------------|------|---------|--------|------|---------------------------------|
| CS-type             | US expectancy | PLC N=22, L-DOPA N=21 | 20.674 | 1,41    | <.001  | .148 | CS+ > CS-, <.001               |
|                     | SCR           | PLC N=21, L-DOPA N=21 | 31.367 | 1,40    | <.001  | .440 | CS+ > CS-, <.001               |
| Reinstatement       | US expectancy | PLC N=22, L-DOPA N=21 | 19.151 | 1,41    | <.001  | .027 | Block 1> Block 2, ps<0.001     |
|                     | SCR           | PLC N=21, L-DOPA N=21 | 19.786 | 1,40    | <.001  | .331 | Block 1> Block 2, <0.001       |
| CS-type * reinstatement | US expectancy | PLC N=22, L-DOPA N=21 | 8.222  | 1,41    | <.001  | .011 | CS+ Block 1> CS+ Block 2, ps< .001 |
|                     | SCR           | PLC N=21, L-DOPA N=21 | 3.989  | 1,40    | 0.053  | .091 | CS+ Block 1> CS+ Block 2, p< .001 |
| CS-type * group     | US expectancy | PLC N=22, L-DOPA N=21 | .042   | 1,41    | .838   | <.001 |                               |
|                     | SCR           | PLC N=21, L-DOPA N=21 | 1.073  | 1,40    | .306   | .026 |                               |
| Reinstatement * group | US expectancy | PLC N=22, L-DOPA N=21 | 0.174  | 1,41    | .678   | <.001 |                               |
|                     | SCR           | PLC N=21, L-DOPA N=21 | 0.002  | 1,40    | .965   | <.001 |                               |
| CS-type * reinstatement group | US expectancy | PLC N=22, L-DOPA N=21 | .103   | 1,41    | .750   | <.001 |                               |
|                     | SCR           | PLC N=21, L-DOPA N=21 | .004   | 1,40    | .951   | <.001 |                               |
| group               | US expectancy | PLC N=22, L-DOPA N=21 | .506   | 1,41    | .481   | .012 |                               |
|                     | SCR           | PLC N=21, L-DOPA N=21 | 1.038  | 1,40    | .867   | <.001 |                               |
Table S9: Reinstatement test (average across 3 trials before vs. after the reinstatement procedure)

| effect                  | measure         | Reinstatement (3 trials) | F     | Df (GG) | P      | Eta²  | Post-hoc (Holm-bonf. corrected) |
|-------------------------|-----------------|--------------------------|-------|---------|--------|-------|---------------------------------|
| CS-type                 | US expectancy   | PLC N=22, L-DOPA N=21    | 13.541| 1,41    | < .001 | .248  | CS+ > CS-, < .001               |
|                         | SCR             | PLC N=21, L-DOPA N=21    | 14.486| 1,40    | < .001 | .226  |                                 |
| Reinstatement           | US expectancy   | PLC N=22, L-DOPA N=21    | 5.360 | 1,41    | .026   | .116  | Block 1> Block 2, p<0.001       |
|                         | SCR             | PLC N=21, L-DOPA N=21    | 4.136 | 1,40    | .004   | .094  | Block 1> Block 2, <0.001        |
| CS-type * reinstatement | US expectancy   | PLC N=22, L-DOPA N=21    | 1.641 | 1,41    | .207   | .038  |                                 |
|                         | SCR             | PLC N=21, L-DOPA N=21    | 0.420 | 1,40    | .521   | .010  |                                 |
| CS-type * group         | US expectancy   | PLC N=22, L-DOPA N=21    | .047  | 1,41    | .829   | <.001 |                                 |
|                         | SCR             | PLC N=21, L-DOPA N=21    | 5.443 | 1,40    | .025   | .120  | See Table S8 for group comparisons |
| Reinstatement * group   | US expectancy   | PLC N=22, L-DOPA N=21    | 2.254 | 1,41    | .141   | .052  |                                 |
|                         | SCR             | PLC N=21, L-DOPA N=21    | .020  | 1,40    | .880   | .001  |                                 |
| CS-type * reinstatement * group | US expectancy | PLC N=22, L-DOPA N=21    | 1.113 | 1,41    | .207   | .038  |                                 |
|                         | SCR             | PLC N=21, L-DOPA N=21    | 1.192 | 1,40    | .282   | .029  |                                 |
| group                   | US expectancy   | PLC N=22, L-DOPA N=21    | .159  | 1,41    | .692   | .004  |                                 |
|                         | SCR             | PLC N=21, L-DOPA N=21    | <.001 | 1,40    | .978   | <.001 |                                 |
S10 CS-type by group comparisons (one-sided Independent Samples T-Test, L-DOPA<Placebo)

| Differential response (CS+>CS-) | t     | df  | p (holm-bonf. corrected) |
|---------------------------------|-------|-----|--------------------------|
| Mean 3 trials before Reinstatement | -0.735 | 40.000 | 0.233                     |
| Mean 3 trials after Reinstatement  | -2.405 | 40.000 | 0.020                     |

Note. For all tests, the alternative hypothesis specifies that L-DOPA group is less than Placebo.

Figure S1 | L-DOPA administration during extinction learning decreases SCRs after reinstatement.

Asterisk indicate a p-value<0.05 for a CS-type by group interaction. See main text figure 2 for illustration of differential responses.
Figure S2 | Enhanced associability related neural signaling in the left amygdala after the administration of L-DOPA. (a) Modelled associability (i.e., attention shift to the omitted US) during the omitted US was related to stronger activation of the left amygdala (MNI xyz: -21, -6, -23; Z = 3.86; P_{FWE-SVC} = .013; displayed at threshold p_{unc} < .005 with bar plot showing parameter estimates (a.u.)) after administration of L-DOPA when compared with placebo controls.